X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Edge Therapeutics begins enrolment in second cohort of EG-1962 Phase I/II trial for aSAH

Yuvraj_pawp by Yuvraj_pawp
6th June 2014
in Americas, Clinical Trials, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase I/II NEWTON trial of its lead product candidate, EG-1962, for the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH).

The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) trial is designed to assess the safety, tolerability and pharmacokinetics of EG-1962 compared with the current standard of care, oral nimodipine, in these patients.

The company is also evaluating patient functional outcomes at 30 and 90 days, which it believes will be indicative of the potential efficacy of EG-1962.

EG-1962 is a polymeric nimodipine microparticle using the company’s Precisa development platform and is being developed to improve patient outcome after aSAH, commonly referred to as ruptured brain aneurysm.

Edge Therapeutics president and chief executive officer Brian Leuthner said: “With each patient cohort, we are collecting a substantial body of safety and efficacy data that we believe will validate our prior experience with EG-1962.

“The Data Safety Monitoring Committee recommendation reflects their confidence in EG-1962 based on the trial results thus far, and allows us to proceed efficiently with the study of EG-1962 as a potential replacement of standard of care treatment for ruptured brain aneurysm patients who receive an intraventricular catheter.

“This allows us to proceed efficiently with the study of EG-1962 as a potential replacement of standard of care treatment for ruptured brain aneurysm patients who receive an intraventricular catheter.”

“We look forward to continued progress of the NEWTON study and to documenting its impact in this important patient population.”

The initiation of patient enrolment follows the protocol-specified review by the NEWTON trial Data Safety Monitoring Committee (DSMC) of the safety and pharmacokinetic data from the first group of the trial, as well as of other exploratory clinical outcomes and non-clinical data.

Based on the review, the DSMC recommended increasing the dose of EG-1962 to 200mg for the second group, as there were no unexpected drug-related serious adverse events, including hypotension, observed with the 100mg dose of EG-1962 in the first group.

Apart from the start of enrolment in second group, the DSMC has approved amending the protocol to allow dose-escalation to proceed without interrupting enrollment between cohorts in the absence of significant safety concerns related to EG-1962.

The decision is expected to save at least 30 days of enrolment time for each group.

Tags: America
Previous Post

Arena begins Phase Ib trial of APD334 to treat autoimmune diseases

Next Post

Gene Expression Profiling Drives Personalized Medicine Worldwide, Finds Frost & Sullivan

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Immune Design starts dosing patients in Phase I study of LV305 immuno-oncology agent

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In